Marakanam Srinivasan Umashankar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marakanam Srinivasan Umashankar has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Bhaswati Das
Department of Pharmaceutics, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu 603203, Tamil Nadu, India
4 shared publications - Koushik Yetukuri
Department of Pharmaceutics, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamil Nadu 603203, India
3 shared publications Manas Ranjan Sahoo
Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India
3 shared publications- Bhuvaneshwari Shanmugam
Department of Pharmaceutics
2 shared publications Damodharan Narayanasamy
Department of Pharmaceutics, SRM College of Pharmacy, Faculty of Medicine and Health Science, SRM Institute of and Technology, Kattankulathur-603203, India
2 shared publicationsV. Anusha
Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, Tamil Nadu, India
2 shared publications
Latest Publications
- 26 October 2026
- Published by Deep Science Publishing
A Textbook of Pharmaceutical Chemistry
We feel pleasure in presenting this book entitled, “A Textbook of Pharmaceutical Chemistry” for meeting the requirements and demands of Diploma in Pharmacy and Bachelor of Pharmacy students. Pharmaceutical (Medicinal) Chemistry is concerned with the design (drug design) of chemical compounds which is focused on quality aspects of medicines and aims to assure fitness for purpose of medicinal products by analyzing and evaluating them as per the quality control standards. We aim to give an easier shape for this notable work which is done for the betterment studies of candidates who are doing Diploma graduation in Pharmacy and a also a basic entity for Degree graduation in Pharmacy. With immense pleasure in preparation of this book in the subject of pharmaceutical chemistry, it is worthful as per the new syllabus given by Directorate of Medical Education, Chennai and TNMGRMU Chennai. We have taken great care to cover the syllabus of Pharmacy without any single omission. The grouping of topics in two volumes is useful for Pharmacy students. It may also be useful for medicinal chemistry, biochemistry and related fields. We have assumed no previous knowledge of the topics covered but the student is expected to be aware of fundamental concepts of medicinal compounds. Finally, we look forward to comments and suggestions from all corners of the profession, teachers as well as students for further modifications and improvements in subsequent editions.
- 26 October 2026
- Published by Deep Science Publishing
A Textbook of Pharmaceutical Chemistry
We feel pleasure in presenting this book entitled, “A Textbook of Pharmaceutical Chemistry” for meeting the requirements and demands of Diploma in Pharmacy and Bachelor of Pharmacy students. Pharmaceutical (Medicinal) Chemistry is concerned with the design (drug design) of chemical compounds which is focused on quality aspects of medicines and aims to assure fitness for purpose of medicinal products by analyzing and evaluating them as per the quality control standards. We aim to give an easier shape for this notable work which is done for the betterment studies of candidates who are doing Diploma graduation in Pharmacy and a also a basic entity for Degree graduation in Pharmacy. With immense pleasure in preparation of this book in the subject of pharmaceutical chemistry, it is worthful as per the new syllabus given by Directorate of Medical Education, Chennai and TNMGRMU Chennai. We have taken great care to cover the syllabus of Pharmacy without any single omission. The grouping of topics in two volumes is useful for Pharmacy students. It may also be useful for medicinal chemistry, biochemistry and related fields. We have assumed no previous knowledge of the topics covered but the student is expected to be aware of fundamental concepts of medicinal compounds. Finally, we look forward to comments and suggestions from all corners of the profession, teachers as well as students for further modifications and improvements in subsequent editions.
- 7 September 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (9) , 586
Development and Optimization of Cefuroxime Axetil -Loaded Ophthalmic Nanowafer for Enhanced Corneal Drug Delivery
- 7 September 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (9) , 586
Development and Optimization of Cefuroxime Axetil -Loaded Ophthalmic Nanowafer for Enhanced Corneal Drug Delivery
- Open Access
- 10 July 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (3) , 57
Targeting PD-1/PD-L1-MAPK1 Signaling by a Novel Synergistic Combination of Rivastigmine and Epigallocatechin in Alzheimer’s Disease: An Integrated In Silico Approach
This study investigates the synergistic therapeutic potential of Rivastigmine (RVG) and Epigallocatechin (EGC) in Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder characterized by neuroinflammation, oxidative stress, and dysregulated signaling pathways. Conventional therapies primarily provide symptomatic relief and target limited pathways, highlighting the need for multi-target strategies with improved efficacy and safety. An integrated in silico approach combining pharmacokinetic evaluation, network pharmacology, molecular docking, and molecular dynamics simulations is used to determine the synergistic potential of RVG and EGC. Pharmacokinetic analysis indicates favorable drug-likeness and acceptable ADME/Tox profiles for both compounds. Network pharmacology identified 146 overlapping targets associated with AD, highlighting key hub genes including NFKB1, MAPK1, STAT1, PRKACA, GRB2, LYN, and PTPN11, which are involved in neuroinflammation, synaptic signaling, and neuronal survival. Functional enrichment analysis indicated significant involvement of MAPK/ERK signaling and immune-regulatory pathways. Importantly, the PD-1/PD-L1 signaling pathway is identified as a novel mechanism connecting neuroimmune modulation with intracellular kinase-driven neurodegeneration. Molecular docking studies showed strong binding affinities of RVG and EGC toward key AD-related targets, particularly MAPK1, supported by stable hydrogen bonding and interaction profiles. Molecular dynamics simulations confirmed stable protein-ligand interactions, with EGC contributing structural stability and RVG exhibiting adaptive flexibility within the binding pocket. These results suggest that the RVG-EGC combination exhibits synergistic potential by simultaneously modulating neuroinflammatory, oxidative stress, and kinase-mediated signaling pathways. The integration of PD-1/PD-L1 and MAPK/ERK signaling provides a novel mechanistic pathway for multi-target therapeutic intervention in AD.
- 10 July 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (3) , 57
Open AccessTargeting PD-1/PD-L1-MAPK1 Signaling by a Novel Synergistic Combination of Rivastigmine and Epigallocatechin in Alzheimer’s Disease: An Integrated In Silico Approach
This study investigates the synergistic therapeutic potential of Rivastigmine (RVG) and Epigallocatechin (EGC) in Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder characterized by neuroinflammation, oxidative stress, and dysregulated signaling pathways. Conventional therapies primarily provide symptomatic relief and target limited pathways, highlighting the need for multi-target strategies with improved efficacy and safety. An integrated in silico approach combining pharmacokinetic evaluation, network pharmacology, molecular docking, and molecular dynamics simulations is used to determine the synergistic potential of RVG and EGC. Pharmacokinetic analysis indicates favorable drug-likeness and acceptable ADME/Tox profiles for both compounds. Network pharmacology identified 146 overlapping targets associated with AD, highlighting key hub genes including NFKB1, MAPK1, STAT1, PRKACA, GRB2, LYN, and PTPN11, which are involved in neuroinflammation, synaptic signaling, and neuronal survival. Functional enrichment analysis indicated significant involvement of MAPK/ERK signaling and immune-regulatory pathways. Importantly, the PD-1/PD-L1 signaling pathway is identified as a novel mechanism connecting neuroimmune modulation with intracellular kinase-driven neurodegeneration. Molecular docking studies showed strong binding affinities of RVG and EGC toward key AD-related targets, particularly MAPK1, supported by stable hydrogen bonding and interaction profiles. Molecular dynamics simulations confirmed stable protein-ligand interactions, with EGC contributing structural stability and RVG exhibiting adaptive flexibility within the binding pocket. These results suggest that the RVG-EGC combination exhibits synergistic potential by simultaneously modulating neuroinflammatory, oxidative stress, and kinase-mediated signaling pathways. The integration of PD-1/PD-L1 and MAPK/ERK signaling provides a novel mechanistic pathway for multi-target therapeutic intervention in AD.
- Open Access
- 30 June 2026
- Published by Informatics Publishing Limited in Toxicology International
- p. 266-276
Toxicological Study of Curcuma longa Essential Oil Against the Aedes aegypti Mosquito Species
Mosquitoes are most vexing bloodsucking insects, transmitting vector-borne diseases. The present study aims to control mosquito species with the essential oil of Curcuma longa. Larvae were maintained at 27 ± 2°C and 60-70% RH under 14:10 h light and darkcycles. 500ml of water containing 30 larvae late 3rd or early 4th instar was used to observe the mortality rate after 0, 1 h, 4 h, 20 h, 24 h, and 48 h of EO treatment using the solubilizer polysorbate 80. The control was set up with the same conditions, only with dechlorinated water. Serial dilutions like 100µL, 500µL, 1000µL, and 2000µL concentrations were used. 100% inhibition was observed for turmeric oil at 100µL at 20 h, 500µL at 20 h, 1000µL at 20 h and 2000µL at 20 h. Observations at 4 h time of 100µL show no mortality and increased concentrations like 500µL@15.67%, 1000µL@26.67%, 2000µL@70%. The Larvicidal potential of % inhibition increased with the increase of oil concentrations, 2000µL, and 70% Larvicidal activity was observed within 4 h. So, in formulations, higher concentrations like 2000µL equivalent will help potential inhibition within 4 h when compared other concentrations. If a low concentration, like 100µL, was sufficient for a gradual like time point and 100% inhibition within 20 h. Results showed that C. longa oil against A. aegypti has potential larvicidal properties, and can be used preventive aspect of vector-borne diseases. The phytochemical profiling carried out using GC–MS analysis confirmed the presence of major bioactive constituents, while FTIR analysis validated the characteristic functional groups responsible for the oil’s biological and physicochemical properties. These analytical findings collectively support the therapeutic and larvicidal potential of the EO. This oil is further planned to be incorporated into mosquito-inhibitory sprays, pharmaceutical topical preparations, pharmaceutical skin creams, etc. Major Findings: Essential oils of C. longa have significant larvicidal activity against A. aegypti mosquito species@2000µL concentration for 4 hours penetration with more than 70% larvicidal property under the above experimental conditions.
- 30 June 2026
- Published by Informatics Publishing Limited in Toxicology International
- p. 266-276
Open AccessToxicological Study of Curcuma longa Essential Oil Against the Aedes aegypti Mosquito Species
Mosquitoes are most vexing bloodsucking insects, transmitting vector-borne diseases. The present study aims to control mosquito species with the essential oil of Curcuma longa. Larvae were maintained at 27 ± 2°C and 60-70% RH under 14:10 h light and darkcycles. 500ml of water containing 30 larvae late 3rd or early 4th instar was used to observe the mortality rate after 0, 1 h, 4 h, 20 h, 24 h, and 48 h of EO treatment using the solubilizer polysorbate 80. The control was set up with the same conditions, only with dechlorinated water. Serial dilutions like 100µL, 500µL, 1000µL, and 2000µL concentrations were used. 100% inhibition was observed for turmeric oil at 100µL at 20 h, 500µL at 20 h, 1000µL at 20 h and 2000µL at 20 h. Observations at 4 h time of 100µL show no mortality and increased concentrations like 500µL@15.67%, 1000µL@26.67%, 2000µL@70%. The Larvicidal potential of % inhibition increased with the increase of oil concentrations, 2000µL, and 70% Larvicidal activity was observed within 4 h. So, in formulations, higher concentrations like 2000µL equivalent will help potential inhibition within 4 h when compared other concentrations. If a low concentration, like 100µL, was sufficient for a gradual like time point and 100% inhibition within 20 h. Results showed that C. longa oil against A. aegypti has potential larvicidal properties, and can be used preventive aspect of vector-borne diseases. The phytochemical profiling carried out using GC–MS analysis confirmed the presence of major bioactive constituents, while FTIR analysis validated the characteristic functional groups responsible for the oil’s biological and physicochemical properties. These analytical findings collectively support the therapeutic and larvicidal potential of the EO. This oil is further planned to be incorporated into mosquito-inhibitory sprays, pharmaceutical topical preparations, pharmaceutical skin creams, etc. Major Findings: Essential oils of C. longa have significant larvicidal activity against A. aegypti mosquito species@2000µL concentration for 4 hours penetration with more than 70% larvicidal property under the above experimental conditions.
- Open Access
- 25 May 2026
- Published by MDPI AG in Preprints.org
Targeting PD-1/PD-L1-MAPK1 Signaling by a Novel Synergistic Combination of Rivastigmine and Epigallocatechin in Alzheimer’s Disease: An Integrated Insilico Approach
This study investigates the synergistic therapeutic potential of Rivastigmine (RVG) and Epigallocatechin (EGC) in Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder characterized by neuroinflammation, oxidative stress, and dysregulated signaling pathways. Conventional therapies primarily provide symptomatic relief and target limited pathways, highlighting the need for multi-target strategies with improved efficacy and safety. An integrated in-silico approach combining pharmacokinetic evaluation, network pharmacology, molecular docking, and molecular dynamics simulations is used to determine the synergistic potential of RVG and EGC. Pharmacokinetic analysis indicates favorable drug-likeness and acceptable ADME/Tox profiles for both compounds. Network pharmacology identified 146 overlapping targets associated with AD, highlighting key hub genes including NFKB1, MAPK1, STAT1, PRKACA, GRB2, LYN, and PTPN11 are involved in neuroinflammation, synaptic signaling, and neuronal survival. Functional enrichment analysis indicated significant involvement of MAPK/ERK signaling and immune-regulatory pathways. Importantly, the PD-1/PD-L1 signaling pathway is identified as a novel mechanistic connecting neuroimmune modulation with intracellular kinase-driven neurodegeneration. Molecular docking studies showed strong binding affinities of RVG and EGC toward key AD-related targets, particularly MAPK1, supported by stable hydrogen bonding and interaction profiles. Molecular dynamics simulations confirmed stable protein-ligand interactions, with EGC contributing structural stability and RVG exhibiting adaptive flexibility within the binding pocket. These results suggest that the RVG-EGC combination exhibits synergistic potential by simultaneously modulating neuroinflammatory, oxidative stress, and kinase-mediated signaling pathways. The integration of PD-1/PD-L1 and MAPK/ERK signaling provides a novel mechanistic pathway for multi-target therapeutic intervention in AD.
- 25 May 2026
- Published by MDPI AG in Preprints.org
Open AccessTargeting PD-1/PD-L1-MAPK1 Signaling by a Novel Synergistic Combination of Rivastigmine and Epigallocatechin in Alzheimer’s Disease: An Integrated Insilico Approach
This study investigates the synergistic therapeutic potential of Rivastigmine (RVG) and Epigallocatechin (EGC) in Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder characterized by neuroinflammation, oxidative stress, and dysregulated signaling pathways. Conventional therapies primarily provide symptomatic relief and target limited pathways, highlighting the need for multi-target strategies with improved efficacy and safety. An integrated in-silico approach combining pharmacokinetic evaluation, network pharmacology, molecular docking, and molecular dynamics simulations is used to determine the synergistic potential of RVG and EGC. Pharmacokinetic analysis indicates favorable drug-likeness and acceptable ADME/Tox profiles for both compounds. Network pharmacology identified 146 overlapping targets associated with AD, highlighting key hub genes including NFKB1, MAPK1, STAT1, PRKACA, GRB2, LYN, and PTPN11 are involved in neuroinflammation, synaptic signaling, and neuronal survival. Functional enrichment analysis indicated significant involvement of MAPK/ERK signaling and immune-regulatory pathways. Importantly, the PD-1/PD-L1 signaling pathway is identified as a novel mechanistic connecting neuroimmune modulation with intracellular kinase-driven neurodegeneration. Molecular docking studies showed strong binding affinities of RVG and EGC toward key AD-related targets, particularly MAPK1, supported by stable hydrogen bonding and interaction profiles. Molecular dynamics simulations confirmed stable protein-ligand interactions, with EGC contributing structural stability and RVG exhibiting adaptive flexibility within the binding pocket. These results suggest that the RVG-EGC combination exhibits synergistic potential by simultaneously modulating neuroinflammatory, oxidative stress, and kinase-mediated signaling pathways. The integration of PD-1/PD-L1 and MAPK/ERK signaling provides a novel mechanistic pathway for multi-target therapeutic intervention in AD.
- 10 February 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (2) , 835-844
Enhancing Solubility and Dissolution of BCS Class II Drug Pitavastatin Calcium by Solid Dispersion Technique Incorporating Second Generation Carriers - Development and characterization
Pitavastatin calcium is used for treatment of conditions like hypercholesterolemia by blocking and reducing cholesterol synthesis. It is a BCS class II drug with poor solubility which further effects the dissolution. The present research focuses on improving the solubility and dissolution of Pitavastatin Calcium by formulating solid dispersions (SD). The solid dispersions were prepared by fusion and kneading method, employing second generation carrier’s Polyethylene glycol 6000 (PEG 6000), Polyvinylpyrrolidone K30 (PVP K30) and Beta Cyclodextrin as hydrophilic polymeric materials in different ratios of drug and polymer (1:1, 1:2, 1:4, 1:6). The formulations were evaluated through FTIR (Fourier transform infrared spectroscopy), DSC (differential scanning Calorimetry), PXRD (Powder X-ray diffraction) and SEM (scanning electron microscopy) studies for major analysis. They were further evaluated for compatibility, solubility, micromeritic properties, In-vitro drug release, percentage yield, drug content and stability studies. The PXRD analysis directed that crystallinity of drug was reduced upon dispersing in carrier, which was visualized by enhanced solubility and dissolution of solid dispersions when compared to pure drug. SEM studies suggested the morphological changes of pure API which existed as rod shaped crystalline material to an reduced crystalline system. The outcomes specified solid dispersions prepared by kneading method exhibited improved properties in comparison to fusion method, particularly the SD comprising beta cyclodextrin PSD20 formulated by kneading method with 1:6 ratio produced high solubility and dissolution with 98.91% drug release in 30 min which was considered as best suitable formulation. It endorses that SD technique has considerably improved the solubility and dissolution rate of API which could be further formulated into suitable dosage form.
- 10 February 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (2) , 835-844
Enhancing Solubility and Dissolution of BCS Class II Drug Pitavastatin Calcium by Solid Dispersion Technique Incorporating Second Generation Carriers - Development and characterization
Pitavastatin calcium is used for treatment of conditions like hypercholesterolemia by blocking and reducing cholesterol synthesis. It is a BCS class II drug with poor solubility which further effects the dissolution. The present research focuses on improving the solubility and dissolution of Pitavastatin Calcium by formulating solid dispersions (SD). The solid dispersions were prepared by fusion and kneading method, employing second generation carrier’s Polyethylene glycol 6000 (PEG 6000), Polyvinylpyrrolidone K30 (PVP K30) and Beta Cyclodextrin as hydrophilic polymeric materials in different ratios of drug and polymer (1:1, 1:2, 1:4, 1:6). The formulations were evaluated through FTIR (Fourier transform infrared spectroscopy), DSC (differential scanning Calorimetry), PXRD (Powder X-ray diffraction) and SEM (scanning electron microscopy) studies for major analysis. They were further evaluated for compatibility, solubility, micromeritic properties, In-vitro drug release, percentage yield, drug content and stability studies. The PXRD analysis directed that crystallinity of drug was reduced upon dispersing in carrier, which was visualized by enhanced solubility and dissolution of solid dispersions when compared to pure drug. SEM studies suggested the morphological changes of pure API which existed as rod shaped crystalline material to an reduced crystalline system. The outcomes specified solid dispersions prepared by kneading method exhibited improved properties in comparison to fusion method, particularly the SD comprising beta cyclodextrin PSD20 formulated by kneading method with 1:6 ratio produced high solubility and dissolution with 98.91% drug release in 30 min which was considered as best suitable formulation. It endorses that SD technique has considerably improved the solubility and dissolution rate of API which could be further formulated into suitable dosage form.
- Open Access
- 7 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 8-19
THE AI REVOLUTION IN PHARMACEUTICALS: INNOVATIONS, CHALLENGES, AND FUTURE PROSPECTS – AN OVERVIEW
Artificial intelligence (AI) is transforming pharmaceutical research and development (R and D), and making measurable improvements in efficiency, precision, and cost-effectiveness in drug research and development. AI-enabled platforms have cut the drug discovery pipeline timelines in comparison to the traditional 4-6 y down to 46 d, along with speeding up compound screening by 1-2 y and reduced clinical trial duration by up to 59% and increased the accuracy of patient selection 80-90%. In formulation optimization artificial neural networks, neuro--fuzzy systems, and hybrid model-based AI models have been able to predict dissolution profile and critical quality attributes with accuracy rates of over 90%, with 30-50% lower experimental workload. In this review, the cross-domain evidence on the use of AI in the continuum of target identification to regulatory integration is thoroughly synthesized and critical evaluations on existing limitations which include data bias, interpretability discrepancy and regulatory ambiguity discussed. It proposes a systematized framework of integration, which places the emphasis on creating high impact pilot projects, in-the-wild testing and further monitoring or observing of models according to the instructions of FDA, EMA and EU AI Act. Synthesizing measures of quantitative values along with practical measures, the present work offers a blueprint of unambiguously converting the ideological potential of AI into implementable, regulator-compatible utilities in pharmaceutical science.
- 7 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 8-19
Open AccessTHE AI REVOLUTION IN PHARMACEUTICALS: INNOVATIONS, CHALLENGES, AND FUTURE PROSPECTS – AN OVERVIEW
Artificial intelligence (AI) is transforming pharmaceutical research and development (R and D), and making measurable improvements in efficiency, precision, and cost-effectiveness in drug research and development. AI-enabled platforms have cut the drug discovery pipeline timelines in comparison to the traditional 4-6 y down to 46 d, along with speeding up compound screening by 1-2 y and reduced clinical trial duration by up to 59% and increased the accuracy of patient selection 80-90%. In formulation optimization artificial neural networks, neuro--fuzzy systems, and hybrid model-based AI models have been able to predict dissolution profile and critical quality attributes with accuracy rates of over 90%, with 30-50% lower experimental workload. In this review, the cross-domain evidence on the use of AI in the continuum of target identification to regulatory integration is thoroughly synthesized and critical evaluations on existing limitations which include data bias, interpretability discrepancy and regulatory ambiguity discussed. It proposes a systematized framework of integration, which places the emphasis on creating high impact pilot projects, in-the-wild testing and further monitoring or observing of models according to the instructions of FDA, EMA and EU AI Act. Synthesizing measures of quantitative values along with practical measures, the present work offers a blueprint of unambiguously converting the ideological potential of AI into implementable, regulator-compatible utilities in pharmaceutical science.
- Open Access
- 7 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 20-32
NANOPARTICLE-EMBEDDED MICRONEEDLES FOR ENHANCED TRANSDERMAL DELIVERY: ADVANCES AND APPLICATIONS
Transdermal drug delivery (TDD) provides a non-invasive alternative to oral and injectable administration, avoiding gastrointestinal degradation and first-pass metabolism. Traditional TDD systems are limited to small, lipophilic drugs and are prone to skin irritation and low bioavailability. Although microneedles (MNs) have several advantages, they also suffer from limited drug-loading capacity, fast drug diffusion, and mechanical fragility. Recent developments combine nanoparticles with microneedles (NEMNs), improving drug stability, bioavailability, and controlled release. The types of MNs (solid, coated, hollow, dissolving, and hydrogel) and considerations regarding materials (silicon, metals, polymers) are presented alongside nanoparticles to enhance therapeutic outcomes. Advancements in manufacturing methods, such as 3D printing and micro molding, have facilitated the controlled deposition of nanoparticles and enabled scalable fabrication. Stimuli-induced NEMNs triggered by pH, glucose, light, and magnetic fields have applications in site-specific drug release for diabetes management, cancer treatment, wound healing, and the treatment of inflammatory ailments. Combining nanomaterials with biodegradable polymers enhances their strength and compatibility with living organisms. Although improvements have been made, nanoparticle stability, scalability, regulatory compliance, and long-term safety remain significant concerns. To encourage clinical translation, future directions will focus on AI-based closed-loop systems, biomaterials that can perform multiple functions, and eco-friendly manufacturing processes. Overcoming these barriers, NEMNs have the potential to serve as patient-centric treatments for both chronic and acute conditions, thereby closing the gap between nanotechnology and minimally invasive therapeutics.
- 7 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 20-32
Open AccessNANOPARTICLE-EMBEDDED MICRONEEDLES FOR ENHANCED TRANSDERMAL DELIVERY: ADVANCES AND APPLICATIONS
Transdermal drug delivery (TDD) provides a non-invasive alternative to oral and injectable administration, avoiding gastrointestinal degradation and first-pass metabolism. Traditional TDD systems are limited to small, lipophilic drugs and are prone to skin irritation and low bioavailability. Although microneedles (MNs) have several advantages, they also suffer from limited drug-loading capacity, fast drug diffusion, and mechanical fragility. Recent developments combine nanoparticles with microneedles (NEMNs), improving drug stability, bioavailability, and controlled release. The types of MNs (solid, coated, hollow, dissolving, and hydrogel) and considerations regarding materials (silicon, metals, polymers) are presented alongside nanoparticles to enhance therapeutic outcomes. Advancements in manufacturing methods, such as 3D printing and micro molding, have facilitated the controlled deposition of nanoparticles and enabled scalable fabrication. Stimuli-induced NEMNs triggered by pH, glucose, light, and magnetic fields have applications in site-specific drug release for diabetes management, cancer treatment, wound healing, and the treatment of inflammatory ailments. Combining nanomaterials with biodegradable polymers enhances their strength and compatibility with living organisms. Although improvements have been made, nanoparticle stability, scalability, regulatory compliance, and long-term safety remain significant concerns. To encourage clinical translation, future directions will focus on AI-based closed-loop systems, biomaterials that can perform multiple functions, and eco-friendly manufacturing processes. Overcoming these barriers, NEMNs have the potential to serve as patient-centric treatments for both chronic and acute conditions, thereby closing the gap between nanotechnology and minimally invasive therapeutics.
- Open Access
- 18 December 2025
- Published by MDPI AG in Preprints.org
Formulation of Rivastigmine-Loaded Nanolipid Mucoadhesive Gel Using Moringa oleifera Mucilage for Enhanced Mucosal Delivery in Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for which current rivastigmine therapies offer limited benefit due to low oral bioavailability, first-pass metabolism, and gastrointestinal side effects. Alternative mucosal routes such as nasal and buccal delivery provide non-invasive, patient-friendly approaches capable of bypassing gastrointestinal degradation while enabling rapid absorption and potentially improving central nervous system exposure. The present study aims to develop a rivastigmine-loaded nanolipid mucoadhesive gel designed for dual mucosal application nasal as well as buccal to prolong residence time, enhance permeability, and sustain drug release. Solid lipid nano carrier composed of a combination of solid and liquid lipids, were selected to achieve improved stability, drug encapsulation, and controlled release compared to conventional solid lipid nanoparticles. To strengthen mucoadhesion and biocompatibility, Moringa oleifera mucilage was incorporated as a natural polymer with excellent swelling and hydrogen-bonding capacity. This novel formulation strategy represents the first reported use of Moringa oleifera mucilage–based gels for rivastigmine mucosal delivery, offering a promising platform for improved bioavailability, better patient compliance, and sustained therapeutic management of Alzheimer’s disease.
- 18 December 2025
- Published by MDPI AG in Preprints.org
Open AccessFormulation of Rivastigmine-Loaded Nanolipid Mucoadhesive Gel Using Moringa oleifera Mucilage for Enhanced Mucosal Delivery in Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for which current rivastigmine therapies offer limited benefit due to low oral bioavailability, first-pass metabolism, and gastrointestinal side effects. Alternative mucosal routes such as nasal and buccal delivery provide non-invasive, patient-friendly approaches capable of bypassing gastrointestinal degradation while enabling rapid absorption and potentially improving central nervous system exposure. The present study aims to develop a rivastigmine-loaded nanolipid mucoadhesive gel designed for dual mucosal application nasal as well as buccal to prolong residence time, enhance permeability, and sustain drug release. Solid lipid nano carrier composed of a combination of solid and liquid lipids, were selected to achieve improved stability, drug encapsulation, and controlled release compared to conventional solid lipid nanoparticles. To strengthen mucoadhesion and biocompatibility, Moringa oleifera mucilage was incorporated as a natural polymer with excellent swelling and hydrogen-bonding capacity. This novel formulation strategy represents the first reported use of Moringa oleifera mucilage–based gels for rivastigmine mucosal delivery, offering a promising platform for improved bioavailability, better patient compliance, and sustained therapeutic management of Alzheimer’s disease.
- Open Access
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 378-390
ISOLATION AND EVALUATION OF NATURAL GUM EXUDATES OF LANNEA COROMANDELICA (HOUTT.) MERR. AS NATURAL POLYMERIC BINDER AND DRUG RELEASE REGULATING AGENT IN COMPARISON WITH SYNTHETIC AND SEMISYNTHETIC POLYMERS
Objective: The present research study aims to isolate the natural gum from Lannea coromandelica (Houtt.) Merr and to analyze and explore the polymeric properties specifically binding property and drug release regulating properties of Lannea gum by formulation of tablets using Ibuprofen as model drug. Methods: The natural Lannea gum was compared with standard synthetic and semi-synthetic polymers like Povidone K30 and Hydroxypropyl methyl cellulose K4M (HPMC K4M) respectively as standard polymers with binding property and drug release regulating property. The process includes formulation of total nine batches, where Lannea gum was used at concentrations of 7, 14, 21 mg as a novel binder and drug release regulating agent with above mentioned as binders and drug release regulating agent along with Avicel PH 102 as diluent and disintegrant, Ibuprofen as model drug, magnesium stearate as lubricant and Aerosil as Glidant with the technique of wet granulation method. The compatibility of formulation blend was analyzed by FTIR studies which indicated the gum is compatible with formulation ingredients. The thermal, surface morphological, physical properties of Lannea gum were identified by DSC, SEM and XRD studies respectively. The micromeritic properties of granules like bulk/tapped density, compressibility index, Hausnner’s ratio, angle of repose indicated satisfactory flow properties. Results: The formulated tablets were evaluated for parameters like weight variation, hardness, disintegration time, drug content and In vitro drug release studies. In conclusion it could be confirmed that at 60 min formulation f3 containing Lannea gum produced drug release of 85.27%, f6 containing Povidone K30 produced drug release of 97.47% and f9 comprising HPMC K4M exhibited 81.15% drug release. Conclusion: The study concludes that Lannea gum unveiled superior binding properties than Povidone K30 and slightly low potential with concern to its binding and drug release regulating properties when compared to HPMC K4M. Hence, Lannea coromandelica gum, can be used as a potential polymer in formulation of tablets as a binder and drug release regulating agent.
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 378-390
Open AccessISOLATION AND EVALUATION OF NATURAL GUM EXUDATES OF LANNEA COROMANDELICA (HOUTT.) MERR. AS NATURAL POLYMERIC BINDER AND DRUG RELEASE REGULATING AGENT IN COMPARISON WITH SYNTHETIC AND SEMISYNTHETIC POLYMERS
Objective: The present research study aims to isolate the natural gum from Lannea coromandelica (Houtt.) Merr and to analyze and explore the polymeric properties specifically binding property and drug release regulating properties of Lannea gum by formulation of tablets using Ibuprofen as model drug. Methods: The natural Lannea gum was compared with standard synthetic and semi-synthetic polymers like Povidone K30 and Hydroxypropyl methyl cellulose K4M (HPMC K4M) respectively as standard polymers with binding property and drug release regulating property. The process includes formulation of total nine batches, where Lannea gum was used at concentrations of 7, 14, 21 mg as a novel binder and drug release regulating agent with above mentioned as binders and drug release regulating agent along with Avicel PH 102 as diluent and disintegrant, Ibuprofen as model drug, magnesium stearate as lubricant and Aerosil as Glidant with the technique of wet granulation method. The compatibility of formulation blend was analyzed by FTIR studies which indicated the gum is compatible with formulation ingredients. The thermal, surface morphological, physical properties of Lannea gum were identified by DSC, SEM and XRD studies respectively. The micromeritic properties of granules like bulk/tapped density, compressibility index, Hausnner’s ratio, angle of repose indicated satisfactory flow properties. Results: The formulated tablets were evaluated for parameters like weight variation, hardness, disintegration time, drug content and In vitro drug release studies. In conclusion it could be confirmed that at 60 min formulation f3 containing Lannea gum produced drug release of 85.27%, f6 containing Povidone K30 produced drug release of 97.47% and f9 comprising HPMC K4M exhibited 81.15% drug release. Conclusion: The study concludes that Lannea gum unveiled superior binding properties than Povidone K30 and slightly low potential with concern to its binding and drug release regulating properties when compared to HPMC K4M. Hence, Lannea coromandelica gum, can be used as a potential polymer in formulation of tablets as a binder and drug release regulating agent.